Acasti pharma announces 1-for-6 reverse stock split

Laval, qb, july 7, 2023 /prnewswire/ -- acasti pharma inc. ("acasti" or the "company") (nasdaq: acst), a late-stage, biopharma company advancing gtx-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced that the company will effect a 1-for-6 reverse split of its issued and outstanding common shares. the reverse stock split will become effective july 10, 2023 at 12:01 a.m.
ACST Ratings Summary
ACST Quant Ranking